Citations

Clear

941 citation(s) found for "Tan, B".

Decreased right ventricular strain before LVAD implantation is associated with adverse early outcome
Lin, Grace , Clavell, Alfredo L. , Stulak, John M., Brady, Peter A. , Liu, M , Ye, Z, Tan, Türkan Seda , Pislaru, Sorin V. , Luis, Sushil Allen , Frantz, Robert P. , Pislaru, Cristina

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.0118 Get It

Abstract Objectives Right ventricular (RV) failure occurring after left ventricular assist device (LVAD) implantation is associated with increased mortality. Purpose We sought to determine whether RV strain by echocardiography predicts outcomes following LVAD. Methods Consecutive patients who underwent continuous flow LVAD placement at our clinic between February 2007 and October 2018 were included. Patients with complex congenital heart disease and arrhythmogenic right ventricular cardiomyopathy were excluded. Baseline characteristics, pre-operative hemodynamic catheterization (1 week) transthoracic echocardiography (1 month) measurements were obtained from the medical record. Speckle tracking RV free wall longitudinal 2D strain was measured using TomTec Imaging System. Univariate and multivariable analysis performed to identify predictors of mortality following LVAD. Results The study group was comprised of 323 patients (mean age 60.8±11.5, 79.9% male) of which 256 had adequate image quality for RV strain. RV strain was impaired in most patients (mean −11.7±3.47). RV strain of −8.1% was identified as predictive of poor outcomes. RV strain did not correlate with other measures of RV dysfunction including pulmonary artery pulsatility index (PAPi) and RVFAC. After adjusting for PAPi, RA pressure, and clinical cumulative risk scores (Matthews, Kormos and Lietz-Miller) impaired RV free wall longitudinal strain (OR: 1.14; 95% CI: 1.01–1.29, p=0.025), tricuspid regurgitation (by vena contracta width (TRvc) (OR: 1.19; 95% CI: 1.05–1.36, p=:0.0021) and smaller LVEDD (OR: 0.95; 95% CI: 0.92–0.99, p:0.023) predicted 30-day all-cause mortality and RV failure. Decreased RV free wall strain also predicted peri-operative mortality (22.58% vs. 4.89%, p=0.0003) and prolonged inotropic support (247.0.±277.4 vs. 122.8±139.3, p=0.024). Conclusions RV free wall strain is a non-invasive independent predictor of 30-day adverse outcomes (RV failure or all-cause mortality) Routine measurement of RV free strain may identify those patients at highest risk for early and long term mortality following LVAD. Funding Acknowledgement Type of funding source: None
International consensus statement on allergy and rhinology: rhinosinusitis 2021
Orlandi, Richard R. , Kingdom, Todd T. , Smith, Timothy L. , Bleier, Benjamin S. , DeConde, Adam S., Luong, Amber , Poetker, David M., Welch, Kevin C. , Wise, Sarah K. , Adappa, Nithin D. , Anselmo‐Lima, Wilma Terezinha , Bachert, Claus , Baroody, Fuad M. , Batra, Pete S., Bernal‐Sprekelsen, Manuel , Bhattacharyya, Neil , Chang, Eugene H., Chowdhury, Naweed I. , Citardi, Martin J. , Cohen, Noah , Conley, David B. , DelGaudio, John M. , Desrosiers, Martin , Douglas, Richard , Eloy, Jean Anderson , Gray, Stacey T. , Gudis, David A. , Hamilos, Daniel L. , Han, Joseph K., Harvey, Richard J. , Hellings, Peter W. , Hopkins, Claire , Hwang, Peter H. , Javer, Amin R. , Kennedy, David W. , Kern, Robert C. , Lee, Heung‐Man , Lee, Jivianne T. , Levy, Joshua M. , Lin, Sandra Y. , Lund, Valerie, McMains, Kevin C. , Metson, Ralph, Naclerio, Robert M. , Oakley, Gretchen M. , Otori, Nobuyoshi , Parikh, Sanjay R., Patel, Zara M. , Peters, Anju T. , Philpott, Carl , Roh, Hwan‐Jung , Rudmik, Luke , Sacks, Raymond , Schlosser, Rodney J. , Sedaghat, Ahmad R. , Senior, Brent A. , Sindwani, Raj , Smith, Kristine A. , Stewart, Michael G. , Suh, Jeffrey D. , Tan, Bruce K. , Drunen, Cornelis M. van , Woodworth, Bradford A. , Wormald, Peter‐John , Wright, Erin D. , Yan, Carol H. , Zhang, Luo , Zhou, Bing , Chang, Michael T. , Bleier, Benjamin , Alt, Jeremiah A , Beswick, Daniel , Eloy, Jean Anderson , Gudis, David A , Holbrook, Eric H , Hopkins, Claire , Javer, Amin R , Jiang, Rong-San , Lal, Devyani , Lee, Heung-Man , Levy, Joshua M , Patel, Zara , Philpott, Carl , Ramakrishnan, Vijay R , Smith, Kristine , Yan, Carol , Zhang, Luo , Schlosser, Rodney J , Harvey, Richard J , Hwang, Peter H , Chang, Michael T , Soler, Zachary M. , Adappa, Nithin D. , Alt, Jeremiah A. , Beswick, Daniel M. , Chandra, Rakesh Kumar , Chang, Eugene H., Chiu, Alexander G. , Cohen, Noam A., Fokkens, Wytske Johanna , Holbrook, Eric H. , Laidlaw, Tanya M. , Lal, Devyani , Lane, Andrew P , Mullol, Joaquim , Passàli, Desiderio , Psaltis, Alkis J. , Ramanathan, Murugappan , Snidvongs, Kornkiat , Turner, Justin H. , Voegels, Richard Louis , Wang, De Yun

Mayo Clinic

International Forum of Allergy & Rhinology | November 25, 2020 | Volume: 11 | Issue: 3 | Pages: 213-739

10.1002/alr.22741 | PMID 33236525 Get It

I. Executive Summary Background The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.
Association of Echocardiographic Left Ventricular End-Systolic Volume and Volume-Derived Ejection Fraction With Outcome in Asymptomatic Chronic Aortic Regurgitation
Anand, Vidhu , Zambito, Elena I., Pellikka, Patricia A. , Thapa, Prabin , Padang, Ratnasari , Enriquez‐Sarano, Maurice , Yang, Li-Tan, Pellikka, Patricia A , Enriquez-Sarano, Maurice , Yang, Li‐Tan , Scott, Christopher G. , Takeuchi, Masaaki , Nishimura, Rick A. , Michelena, Héctor I.

Mayo Clinic

JAMA Cardiology | November 4, 2020 | Volume: 6 | Issue: 2 | Pages: 189

10.1001/jamacardio.2020.5268 | PMID 33146680 Get It

Contemporary differences between bicuspid and tricuspid aortic valve in chronic aortic regurgitation
Benfari, Giovanni , Eleid, Mackram F. , Scott, Christopher G. , Nkomo, Vuyisile T. , Pellikka, Patricia A. , Anavekar, Nandan S., Enriquez‐Sarano, Maurice , Michelena, Héctor I. , Yang, Li-Tan, Eleid, Mackram, Scott, Christopher , Nkomo, Vuyisile T , Pellikka, Patricia A , Michelena, Hector I , Enriquez-Sarano, Maurice , Benfari, Giovanni , Yang, Li‐Tan

Mayo Clinic

Heart | October 27, 2020 | Volume: 107 | Issue: 11 | Pages: 916-924

10.1136/heartjnl-2020-317466 | PMID 33109713 Get It

Objective To comprehensively explore contemporary differences between bicuspid aortic valve (BAV) and tricuspid aortic valve (TAV) patients with chronic haemodynamically significant aortic regurgitation (AR). Methods Consecutive patients with chronic ≥moderate-severe AR from a tertiary referral centre (2006–2017) were included. All-cause mortality, surgical indications and aortic valve surgery (AVS) were analysed. Results Of 798 patients (296 BAV-AR, age 46±14 years; 502 TAV-AR, age 67±14 years, p<0.0001) followed for 5.5 (IQR: 2.9–9.2) years, 403 underwent AVS (repair in 96) and 154 died during follow-up. The 8-year AVS incidence was 60%±3% versus 53%±3% for BAV-AR and TAV-AR, respectively (p=0.014). The unadjusted (real-life) 8-year total survival was 93%±7% versus 71%±2% for BAV-AR and TAV-AR, respectively (p<0.0001), and became statistically insignificant after sole adjustment for age (p=0.14). The within-group relative risk of death in BAV-AR patients demonstrated a large age-dependent increase (two fold at 50–55 years, up to 10-fold at 70 years). The presence of baseline symptoms was significantly associated with death for both BAV-AR (p=0.039) and TAV-AR (p<0.0001), but the strength of the association decreased with age adjustment for BAV-AR (age-adjusted HR 2.43 (0.92–6.39), p=0.07) and not for TAV-AR (age-adjusted HR, 2.3 (1.6–3.3), p<0.0001). As compared with general population, TAV-AR exhibited baseline excess risk which further increased at left ventricular ejection fraction (LVEF) <60% and left ventricular end-systolic dimension index (LVESDi) >20 mm/m2; similar thresholds were observed for BAV-AR patients. Conclusion BAV-AR patients were two decades younger than TAV-AR and underwent AVS more frequently, resulting in a considerable real-life survival advantage for BAV-AR that was determined primarily by age and not valve anatomy. Pragmatically, regardless of valve anatomy, patients with haemodynamically significant AR and age >50–55 years require a low-threshold for surgical referral to prevent symptom development where LVEF <60% and LVESDi >20 mm/m2 seem appropriate referral thresholds.
Galactose treatment of a PGM1 patient presenting with restrictive cardiomyopathy
Donoghue, Sarah , White, Susan M. , Kowalski, Remi , Yaplito‐Lee, Joy , Donoghue, Sarah E , Tan, Tiong Yang , Morava, Éva

Mayo Clinic

JIMD Reports | October 20, 2020 | Volume: 57 | Issue: 1 | Pages: 29-37

10.1002/jmd2.12177 | PMID 33473337 Get It

AbstractWe report a patient diagnosed with PGM1‐CDG at 11 years of age after two biallelic likely pathogenic variants in PGM1 were found on research genomic sequencing. To our knowledge, he is the first patient with PGM1‐CDG to be reported with a restrictive cardiomyopathy. Other clinical manifestations included cleft palate, asymptomatic elevated transaminases, intellectual disability and myopathy resulting in exercise intolerance. He was trialed on oral galactose therapy in increasing doses for 18 weeks to assess if there was any biochemical and clinical benefit. His galactose was continued for a further 9 months beyond the initial galactose treatment period due to improvements in exercise tolerance and myopathy. Treatment with galactose demonstrated an improvement in liver function and myopathy with improved exercise tolerance. Treatment with galactose for 15 months did not change heart function and exercise stress test results were stable.
Reactive Eosinophil Proliferations in Tissue and the Lymphocytic Variant of Hypereosinophilic Syndrome
King, Rebecca L. , Tan, Brent , Craig, Fiona E. , Horny, Hans-Peter, Kelemen, Katalin, Reichard, Kaaren K. , Wang, Sa A. , Zamò, Alberto , Zamò, Alberto , George, Tracy I. , Orazi, Attilio , Rimsza, Lisa M. , Quintanilla‐Martínez, Leticia

Mayo Clinic

American Journal of Clinical Pathology | October 3, 2020 | Volume: 155 | Issue: 2 | Pages: 211-238

10.1093/ajcp/aqaa227 | PMID 33367482 Get It

Abstract Objectives The 2019 Society for Hematopathology and European Association for Haematopathology Workshop reviewed the spectrum of neoplastic, nonneoplastic, and borderline entities associated with reactive eosinophilia in tissue. Methods The workshop panel reviewed 46 cases covered in 2 workshop sessions. Results The 46 cases were presented with their consensus diagnoses during the workshop. Reactive eosinophilia in lymph nodes and other tissues may be accompanied by or be distinct from peripheral blood eosinophilia. Reactive etiologies included inflammatory disorders such as Kimura disease and IgG4-related disease, which may show overlapping pathologic features and reactions to infectious agents and hypersensitivity (covered in a separate review). Hodgkin, T-cell, and B-cell lymphomas and histiocytic neoplasms can result in reactive eosinophilia. The spectrum of these diseases is discussed and illustrated through representative cases. Conclusions Reactive eosinophilia in lymph nodes and tissues may be related to both nonneoplastic and neoplastic lymphoid proliferations and histiocytic and nonhematolymphoid processes. Understanding the differential diagnosis of reactive eosinophilia and the potential for overlapping clinical and pathologic findings is critical in reaching the correct diagnosis so that patients can be treated appropriately.
A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer
Kim, Richard D. , Tan, Elaine , Wang, Emily, Chen, Dung‐Tsa, Cao, Biwei , Masawi, Fadzai, Machado, Cindy, Yu, James , Kim, Richard , Mahipal, Amit , Kim, Dae Won

Mayo Clinic

The Oncologist | September 11, 2020 | Volume: 25 | Issue: 12 | Pages: e1893-e1899

10.1634/theoncologist.2020-0759 | PMID 32776632 Get It

Abstract Lessons Learned The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy. Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily. The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma. Background The RAS/RAF/MEK/ERK signaling pathway is associated with proliferation and progression of hepatocellular carcinoma (HCC). Preclinical data suggest that paradoxical activation of the MAPK pathway may be one of the resistance mechanisms of sorafenib; therefore, we evaluated trametinib plus sorafenib in HCC. Methods This was a phase I study with a 3+3 design in patients with treatment-naïve advanced HCC. The primary objective was safety and tolerability. The secondary objective was clinical efficacy. Results A total of 17 patients were treated with three different doses of trametinib and sorafenib. Two patients experienced dose-limiting toxicity, including grade 4 hypertension and grade 3 elevation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/bilirubin over 7 days. Maximum tolerated dose was trametinib 1.5 mg daily and sorafenib 200 mg twice a day. The most common grade 3/4 treatment-related adverse events were elevated AST (37%) and hypertension (24%). Among 11 evaluable patients, 7 (63.6%) had stable disease with no objective response. The median progression-free survival (PFS) and overall survival (OS) were 3.7 and 7.8 months, respectively. Phosphorylated-ERK was evaluated as a pharmacodynamic marker, and sorafenib plus trametinib inhibited phosphorylated-ERK up to 98.1% (median: 81.2%) in peripheral blood mononuclear cells. Conclusion Trametinib and sorafenib can be safely administered up to trametinib 1.5 mg daily and sorafenib 200 mg twice a day with limited anticancer activity in advanced HCC.
The Effect of Including Benchmark Prevalence Data of Common Imaging Findings in Spine Image Reports on Health Care Utilization Among Adults Undergoing Spine Imaging
Jarvik, Jeffrey G. , Meier, Eric N. , James, Kathryn T., Tan, Katherine W., Kessler, Larry G. , Suri, Pradeep , Kallmes, David F. , Cherkin, Daniel C., Deyo, Richard A. , Sherman, Karen J. , Halabi, Safwan S. , Comstock, Bryan A. , Avins, Andrew L. , Friedly, Janna , Lavallee, Danielle C. , Stephens, Kari A. , Turner, Judith A. , Bresnahan, Brian W., Luetmer, Patrick H. , Gold, Laura S. , Rundell, Sean D. , Griffith, Brent D , Heagerty, Patrick J. , Stephens, Kari A

Mayo Clinic

JAMA Network Open | September 4, 2020 | Volume: 3 | Issue: 9 | Pages: e2015713

10.1001/jamanetworkopen.2020.15713 | PMID 32886121 Get It

Abstract CT118: Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer: Experiences of pancreatic ductal adenocarcinoma (PDAC) patients
Tan, Benjamin , Aranha, Olivia , Park, Haeseong , Boice, Nicholas , Wang‐Gillam, Andrea , McWilliams, Robert R. , Lockhart, A. Craig , Suresh, Rama , Lim, Kian-Huat , Pedersen, Katrina S. , Trikalinos, Nikolaos A. , Ratner, Lee , DeNardo, David G

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: CT118-CT118

10.1158/1538-7445.am2020-ct118 Get It

Abstract Background: Focal adhesion kinase (FAK) is consistently hyperactivated in multiple tumor types including PDAC. Our preclinical work showed that FAK and PD-1 inhibitors elicit significant tumor regression, and that combining FAK and PD-1 inhibitors with gemcitabine achieves a maximal response. This suggests the need for a cytotoxic agent to bolster antigen presentation. Defactinib is an orally available, well-tolerated, potent FAK inhibitor. Methods: This study included a dose escalation phase (all solid tumors) and dose expansion phase (metastatic PDAC). A 3+3 design with five dose levels was used in the dose escalation phase. For the expansion phase, 10 PDAC patients with stable disease on front-line gemcitabine/nab-paclitaxel were enrolled in the Maintenance cohort (A), while 10 patients who progressed on at least one line of therapy were enrolled in the Refractory cohort (B). Pre and on-treatment biopsied were collected from all PDAC patients. The primary endpoint was to determine the recommended phase 2 dose (RP2D). Secondary endpoints included safety, toxicity, objective response rate, progression-free survival (PFS) and overall survival (OS). The exploratory endpoints included developing a molecular and immune profile for treatment response. Results: In dose escalation, the common low grade (G1/2) treatment-emergent adverse events included fatigue, anorexia, nausea and vomiting. No DLTs were seen. The RP2D was defactinib 400mg twice daily, gemcitabine 1000 mg/m2 days 1, 8 and pembrolizumab 200mg day 1 of a 21-day cycle. Safety and toxicity results in the escalation cohort were reported at the 2018 ASCO Annual Meeting. Among 8 evaluable PDAC patients enrolled on the dose escalation phase, we observed 1 (13%) partial response (PR), 3 (38%) stable disease (SD), 4 (50%) progressive disease (PD). In the Maintenance cohort, 1 (10%) PR, 6 (60%) SD, and 3 (30%) PD were observed. Two patients in the Maintenance cohort remain on study, and the median time on treatment was 4.6 months. In the Refractory cohort, 5 (50%) had SD, 4 (40%) PD, 1 not evaluable; median PFS was 2.9 months and median OS was 7.6 months. Interestingly, two confirmed PR patients both have MSS disease. Paired biopsies in PDAC patients show increased proliferating CD8+ T cells, while Tregs, macrophages, and stromal density decrease with treatment. Conclusions: The combination regimen was well tolerated. Encouraging efficacy signals were observed in both Maintenance and Refractory cohorts. Updated outcomes and correlative analyses are forthcoming. Citation Format: Andrea Wang-Gillam, Robert McWilliams, A. Craig Lockhart, Benjamin R Tan, Rama Suresh, Kian-Huat Lim, Katrina S. Pedersen, Nikolaos Trikalinos, Olivia Aranha, Haeseong Park, Lee Ratner, Nicholas Boice, David G. Denardo. Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer: Experiences of pancreatic ductal adenocarcinoma (PDAC) patients [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT118.
Abstract 4761: Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism
Docanto, Maria, Sutherland, Peter , Shepherd, Andrew , Tan, Winston , Horvath, Lisa G. , Lin, Hui‐Ming , Mak, Blossom , Mahon, Kate Lynette , Yeung, Nicole K. , Azad, Arun , Kohli, Manish , Meikle, Peter J. , Butler, Lisa M.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 4761-4761

10.1158/1538-7445.am2020-4761 Get It

Abstract Background: Obesity is a well established risk factor not only for increased prostate cancer incidence, but for poorer survival from prostate cancer. However, there is limited knowledge on the role of the circulating lipidome in prostate cancer. In order to target lipid metabolism optimally, it is critical to understand the spectrum of changes in circulating lipid profiles and the association with clinical outcome across the natural history of prostate cancer. Aim: To assess the relationship between the plasma lipidome and clinical outcome in localized and metastatic prostate cancer. Methods: Liquid chromatography-tandem mass spectrometry was used to quantitate over 500 lipid species in plasma samples from 3 cohorts (1) 389 men with localized prostate cancer, (2) 44 men with metastatic hormone-sensitive prostate cancer (mHSPC), and (3) 137 men with metastatic castration-resistant prostate cancer (CRPC). Associations between circulating lipids with metastatic relapse, androgen-deprivation therapy (ADT) failure or overall survival for each relevant disease stage were examined by latent class analysis and cox regression. Results: Circulating lipid profiles displaying elevated levels of ceramides were associated with metastatic relapse in localized prostate cancer (HR 5.8, 95% CI 3.0-11, P 1 × 10−6), early ADT failure in mHSPC (HR 2.4, 95% CI 1.1-5.3, P 0.03), and shorter overall survival in CRPC (HR 2.5, 95% CI 1.7-3.7, P 2 × 10−6). ADT failure in mHSPC and shorter overall survival in CRPC were also associated with elevated levels of other sphingolipids (sphingomyelins, hexosylceramides). The prognostic significance of the high risk lipid profiles in localized prostate cancer was independent of clinicopathological characteristics (lipid profile HR 4.7, 95%CI 2.4-9.3, P 7 × 10−6) when modeled with Gleason score (P&lt;0.0001) and pathological stage (P&lt;0.0001). Furthermore, the circulating lipid profiles were independent of metabolic factors (localized prostate cancer lipid profile HR 8.2, 95% CI 2.6-25, P 0.0003 when modeled with diabetes, statin, hypertension, body mass index [BMI]; CRPC lipid profile HR 2.6, 95% CI 1.7-3.8, P x10−6 when modeled with BMI). Conclusion: Elevated circulating ceramides are associated with poorer clinical outcomes across the natural history of prostate cancer (from localized to metastatic hormone-sensitive to metastatic castration resistant prostate cancer). This demonstrates that aberrant lipid metabolism in the patients occurs early in prostate cancer and could be therapeutically targeted in prospective clinical trials to improve prostate cancer outcomes. Citation Format: Lisa Glen Horvath, Hui-Ming Lin, Blossom Mak, Kate Mahon, Nicole Yeung, Maria Docanto, Peter Sutherland, andrew Shepherd, Winston Tan, Arun Azad, Manish Kohli, Peter Meikle, Lisa Butler. Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4761.